The Health Resources and Services Administration in its FY 2019 budget justification says the development of a ceiling-price verification system is a priority, but the agency must first complete the civil monetary penalty rule, InsideHealthPolicy reports.
Another priority for FY 2019 includes keeping an eye on the 340B prices voluntarily submitted by drug manufacturers.
Per the report, the HRSA under the Affordable Care Act must provide online access to ceiling prices cleared by the federal agency for 340B facilities.
Click here to read the full report on InsideHealthPolicy. (Paid subscription required)